Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384281 | 1.00 | ALDH1A1 (0.74) | ALDH1A1MAPK1SMN1; SMN2TAAR1MEN1 | |
| SCHEMBL2132960 | 0.88 | ALDH1A1 (0.63) | ALDH1A1MAPK1SMN1; SMN2TAAR1MEN1 | |
| Hydrochloric Acid SCHEMBL3758009 | 0.86 | ALDH1A1 (0.61) | ALDH1A1MAPK1SMN1; SMN2TAAR1MEN1 | |
| SCHEMBL11385463 | 0.86 | ALDH1A1 (0.61) | ALDH1A1MAPK1SMN1; SMN2TAAR1MEN1 | |
| SCHEMBL29434700 | 0.85 | ALDH1A1 (0.55) | ALDH1A1MAPK1SMN1; SMN2TAAR1MEN1 | |
| SCHEMBL3752932 | 0.85 | ALDH1A1 (0.55) | ALDH1A1MAPK1SMN1; SMN2TAAR1MEN1 | |
| SCHEMBL3340047 | 0.85 | SMN1; SMN2 (1.00) | ALDH1A1MAPK1SMN1; SMN2TAAR1MEN1 | |
| SCHEMBL29898229 | 0.85 | SMN1; SMN2 (1.00) | ALDH1A1MAPK1SMN1; SMN2TAAR1MEN1 | |
| SCHEMBL25282673 | 0.84 | ALDH1A1 (0.59) | ALDH1A1MAPK1SMN1; SMN2TAAR1MEN1 | |
| SCHEMBL8686340 | 0.84 | SMN1; SMN2 (0.80) | ALDH1A1MAPK1SMN1; SMN2TAAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313981-B1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4676922-A1 | BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS | Astrazeneca AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| EP-3768260-B1 | OXADIAZOLE COMPOUNDS AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-10-08 | — | — | EP | disclosed |
| EP-4619397-A1 | SALT-INDUCIBLE KINASES (SIK) INHIBITORS AND METHODS OF USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-09-24 | — | — | EP | disclosed |
| EP-3952870-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO LTD (CN) | 2025-09-24 | — | — | EP | disclosed |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER INC. (US) | 2025-08-21 | — | — | US | disclosed |
| WO-2025134150-A1 | BIPHENYL PYRIDINE RIGID COMPOUNDS WITH POLYCYCLIC HETEROCYCLES USEFUL AS DUAL IMMUNE CHECKPOINT INHIBITORS | NATCO PHARMA LIMITED (IN) | 2025-06-26 | — | — | WO | disclosed |
| US-20250177539-A1 | ER DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2025-06-05 | — | — | US | disclosed |
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC | 2025-05-15 | — | — | US | disclosed |
| US-20250122184-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20040209866-A1 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-10-21 | — | — | US | disclosed |
| WO-2004083207-A1 | NAPHTHYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040157875-A1 | 1, 6-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | disclosed |
| EP-1432710-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1432711-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | Bayer Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-6677352-B1 | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027113-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154109-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | SCN8A, TRPV1, SCNN1A | ALDH1A1 2842/4885MAPK1 2312/4885SMN1; SMN2 741/4885 |
| US-20040157875-A1 | 1, 6-Naphthyridine derivatives and their use to treat diabetes and related disorders | GLP1R, NQO1, UQCRC1 | ALDH1A1 850/4885MAPK1 894/4885SMN1; SMN2 2827/4885 |
| US-20040209866-A1 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | SLC5A1, NQO1, GLP1R | ALDH1A1 754/4885MAPK1 954/4885SMN1; SMN2 2937/4885 |
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | UQCRC1, GLP1R, SLC5A1 | ALDH1A1 820/4885MAPK1 1071/4885SMN1; SMN2 3159/4885 |
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | ALDH1A1 292/4885MAPK1 341/4885SMN1; SMN2 2135/4885 |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | NRAS, KRAS, BRAF | ALDH1A1 1249/4885MAPK1 15/4885SMN1; SMN2 2423/4885 |
| US-20250122184-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | ALDH1A1 721/4885MAPK1 1686/4885SMN1; SMN2 1161/4885 |
| US-20250177539-A1 | ER DEGRADERS AND USES THEREOF | ESR1, ESR2, ESRRA | ALDH1A1 1672/4885MAPK1 2785/4885SMN1; SMN2 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.